10-K/A: Amedisys Corrects Share Count in Amended 10-K Filing

Amedisys files an amendment to its 2024 Annual Report to correct the number of outstanding shares of common stock as of February 21, 2025.

Summary

• Amedisys, Inc. has filed an amendment (Form 10-K/A) to its original Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
• The amendment corrects the number of outstanding shares of common stock as of February 21, 2025, which is now stated as 32,810,291 shares.
• The filing also includes updated certifications from the principal executive officer and principal financial officer, as required by Section 302 of the Sarbanes-Oxley Act of 2002.
• No other changes were made to the original filing, and the original filing continues to speak as of its original date.

Sentiment

Score: 7

Explanation: The document is a routine correction of a previously filed report, indicating a neutral to slightly positive sentiment as the company is ensuring accurate reporting.

Positives

• The company is taking steps to ensure accurate reporting by correcting an error in its original filing.
• Updated certifications from the CEO and CFO provide assurance regarding the accuracy of the report.

Management Comments

• Richard Ashworth, Chief Executive Officer, and Scott G. Ginn, Chief Operating Officer, Executive Vice President and Chief Financial Officer, certified the accuracy of the amended report.

Industry Context

This is a standard regulatory filing update to ensure accuracy in financial reporting, which is crucial for maintaining investor confidence in the healthcare services industry.

Key Dates

Keywords

Form 10-K/A, amendment, Amedisys, shares outstanding, financial reporting, Sarbanes-Oxley Act, certification